Vincerx Pharma analyst ratings
Vincerx Pharma analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/08/2022 | 306.09% | Cantor Fitzgerald | $22 → $8 | Maintains | Overweight |
| 06/07/2022 | 204.57% | B. Riley Securities | $12 → $6 | Maintains | Buy |
| 06/07/2022 | 103.05% | Chardan Capital | $11 → $4 | Maintains | Buy |
| 06/07/2022 | 204.57% | SVB Leerink | $19 → $6 | Maintains | Outperform |
| 05/13/2022 | 458.38% | Chardan Capital | $14 → $11 | Maintains | Buy |
| 05/13/2022 | 864.47% | SVB Leerink | $20 → $19 | Maintains | Outperform |
| 03/30/2022 | 915.23% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 03/30/2022 | 1321.32% | HC Wainwright & Co. | $25 → $28 | Maintains | Buy |
| 01/14/2022 | 1169.04% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/23/2021 | 1169.04% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 11/01/2021 | 1118.27% | SVB Leerink | → $24 | Initiates Coverage On | → Outperform |
| 09/13/2021 | 1422.84% | Laidlaw & Co. | → $30 | Initiates Coverage On | → Buy |
| 08/25/2021 | 1219.8% | B. Riley Securities | → $26 | Initiates Coverage On | → Buy |
| 08/13/2021 | 1422.84% | Chardan Capital | $33 → $30 | Maintains | Buy |
| 01/06/2021 | 1575.13% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 06/08/2022 | 306.09% | 坎托·菲茨杰拉德 | 22 美元 → 8 美元 | 维护 | 超重 |
| 2022 年 7 月 6 日 | 204.57% | B. 莱利证券 | 12 美元 → 6 美元 | 维护 | 买 |
| 2022 年 7 月 6 日 | 103.05% | 查丹资本 | 11 美元 → 4 美元 | 维护 | 买 |
| 2022 年 7 月 6 日 | 204.57% | SVB Leerink | 19 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/13/2022 | 458.38% | 查丹资本 | 14 美元 → 11 美元 | 维护 | 买 |
| 05/13/2022 | 864.47% | SVB Leerink | 20 美元 → 19 美元 | 维护 | 跑赢大盘 |
| 03/30/2022 | 915.23% | SVB Leerink | 24 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 03/30/2022 | 1321.32% | HC Wainwright & Co. | 25 美元 → 28 美元 | 维护 | 买 |
| 2022 年 1 月 14 日 | 1169.04% | HC Wainwright & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 12/23/2021 | 1169.04% | 坎托·菲茨杰拉德 | → 25 美元 | 启动覆盖范围开启 | → 超重 |
| 11/01/2021 | 1118.27% | SVB Leerink | → 24 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 09/13/2021 | 1422.84% | Laidlaw & Co. | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 8 月 25 日 | 1219.8% | B. 莱利证券 | → 26 美元 | 启动覆盖范围开启 | → 购买 |
| 08/13/2021 | 1422.84% | 查丹资本 | 33 美元 → 30 美元 | 维护 | 买 |
| 01/06/2021 | 1575.13% | 查丹资本 | → 33 美元 | 启动覆盖范围开启 | → 购买 |
Vincerx Pharma Questions & Answers
Vincerx Pharma 问题与解答
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by B. Riley Securities on June 7, 2022. The analyst firm set a price target for $6.00 expecting VINC to rise to within 12 months (a possible 204.57% upside). 13 analyst firms have reported ratings in the last year.
B. Riley Securities于2022年6月7日公布了Vincerx Pharma（纳斯达克股票代码：VINC）的最新目标股价。该分析公司将目标股价定为6.00美元，预计VINC将在12个月内升至12个月内（可能上涨204.57％）。去年有13家分析公司公布了评级。
The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by B. Riley Securities, and Vincerx Pharma maintained their buy rating.
Vincerx Pharma（纳斯达克股票代码：VINC）的最新分析师评级由B. Riley Securities提供，Vincerx Pharma维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on June 7, 2022 so you should expect the next rating to be made available sometime around June 7, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Vincerx Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Vincerx Pharma的最新评级是在2022年6月7日公布的，因此您应该预计下一个评级将在2023年6月7日左右公布。
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $12.00 to $6.00. The current price Vincerx Pharma (VINC) is trading at is $1.97, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Vincerx Pharma（VINC）评级维持不变，目标股价为12.00美元至6.00美元。Vincerx Pharma（VINC）目前的交易价格为1.97美元，超出了分析师的预期区间。